menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

What Biotech Companies Want in Generic Legislation

Program Information
Recommended
What Biotech Companies Want in Generic Legislation
RestartResume
There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so...
  • Overview

    There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market. 

Facebook Comments

Programs 11/19/19

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.